

CNS SPECTRUMS[®]

THE INTERNATIONAL JOURNAL OF NEUROPSYCHIATRIC MEDICINE

ORIGINAL RESEARCH

An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

A.H. Clayton, S.G. Kornstein, G. Rosas, C. Guico-Pabia, and K.A. Tourian

Aripiprazole Augmentation in Major Depressive Disorder: *A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants*

R.M. Berman, M. Fava, M.E. Thase, M.H. Trivedi, R. Swanink, R.D. McQuade,
W.H. Carson, D. Adson, L. Taylor, J. Hazel, and R.N. Marcus

CASE REPORTS

Attenuation of Apparent New-Onset Ocular Tics with Successful Treatment of PTSD

P.C. Hayes, C.L. Weber, M.B. Gallagher, and G.J. Drouillard

Theta Burst Stimulation in the Treatment of Incapacitating Tinnitus Accompanied by Severe Depression

S.R. Soekadar, C. Arfeller, A. Rilk, S.K. Plontke, and C. Plewnia


TRENDS IN PSYCHOPHARMACOLOGY

Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: *Overview and Finding the Focus*

S.M. Stahl and R.L. Davis

COMMUNIQUE

Selective Benefit of Donepezil on Oral Naming in Alzheimer's Disease in Men Compared to Women

A large elephant is the central focus of the image, positioned in an office environment. A red banner is draped over its back, featuring a list of negative personality traits in white, bold, sans-serif capital letters. In the foreground, a man in a white lab coat sits at a desk, facing a woman and a young boy who are also seated at the desk. The desk is cluttered with papers, a telephone, and other office supplies. The background shows a window with a view of a cloudy sky.

**RESENTFUL
DEFIANT ANGRY
ARGUMENTATIVE
LOSES TEMPER
IRRITABLE¹**

ADHD with oppositional symptoms

As important to treat as it is to discuss

Oppositional symptoms—the missing piece of the ADHD symptom discussion

40% to 60% of children with ADHD present with oppositional symptoms.²⁻⁵ Many parents, however, are not aware of the relationship of these symptoms and ADHD or how they can exacerbate the disorder.⁶

How many of these patients are in your practice?

Initiating frank and open discussions with parents and using diagnostic tools that include oppositional symptoms may further refine a comprehensive treatment plan for ADHD with oppositional symptoms.

40% to 60%
of children with ADHD
present with oppositional
symptoms²⁻⁵

Visit **APA Booth 1628** to find out how you can start the discussion to help manage oppositional symptoms and address what was once left unsaid.

References: 1. Conners CK. Conners 3™—parent. North Tonawanda, NY: Multi-Health Systems Inc; 2008. 2. Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents. *Child Adolesc Psychiatr Ment Health*. 2008;2(1):15. 3. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 1999;56:1073-1086. 4. Attention-deficit disorders with oppositionality and aggression. In: Brown TE, ed. *Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults*. Arlington, VA: American Psychiatric Publishing, Inc; 2000. 5. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. *J Am Acad Child Adolesc Psychiatry*. 1996;35:1193-1204. 6. Findling RL, Connor DF, Wigal T, Eagan C, Onofrey MN. A linguistic analysis of in-office dialogue among psychiatrists, parents, and child and adolescent patients with ADHD [published online ahead of print September 2, 2008]. *J Atten Disord*. 2008. <http://jadsagepub.com/cgi/content/abstract/1087054708323002v1>.

EDITORS

EDITOR

Eric Hollander, MD
Institute of Clinical Neuroscience
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Cape Town
Cape Town, South Africa

ASIA

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Robert M. Berman, MD
Anita H. Clayton, MD
CPT(P) Patrick C. Hayes, MD
Surjo R. Soekadar, MD

FIELD EDITOR

Michael Trimble, MD, FRCP, FRPpsych

COLUMNISTS

Uriel Halbriech, MD
Stefano Pallanti, MD, PhD
Thomas E. Schlaepfer, MD
Stephen M. Stahl, MD, PhD
Dan J. Stein, MD, PhD

CME COURSE DIRECTOR

James C.-Y. Chou, MD

SUPPLEMENT EDITOR

Joseph Zohar, MD

EDITORIAL ADVISORY BOARD

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA

Mark S. George, MD
Medical University of South Carolina
Charleston, SC

Richard B. Lipton, MD
Albert Einstein College of Medicine
Bronx, NY

C. Warren Olanow, MD, FRCP
Mount Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY

Stephen D. Silberstein, MD, FACP
Thomas Jefferson University
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPpsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Dennis S. Charney, MD
Mount Sinai School of Medicine
New York, NY

Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Martin B. Keller, MD
Brown Medical School
Providence, RI

Lorin M. Koran, MD
Stanford University School of Medicine
Stanford, CA

Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy

Katharine Phillips, MD
Brown Medical School
Providence, RI

Harold A. Pincus, MD
Columbia University
New York, NY

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA

Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany

Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA

Norman Sussman, MD
New York University Medical School
New York, NY

Michael E. Thase, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

Madhukar H. Trivedi, MD
University of Texas Southwestern Medical Center
Dallas, TX

Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, TX

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

PUBLICATION STAFF

CEO & PUBLISHER

Darren L. Brodeur

VP, MANAGING EDITOR

Christopher Naccari

VP, HUMAN RESOURCES

Kimberly A. Brodeur

GLOBAL ACCOUNT MANAGER

Evan Frieder

SENIOR EDITORS

Dena Croog
José Ralat

ASSOCIATE EDITOR

Lonnie Stoltzfoos

ASSISTANT EDITOR

Carlos Perkins, Jr.

SENIOR ACQUISITIONS EDITOR

Lisa Arrington

ACQUISITIONS EDITOR

Virginia Jackson

EDITORIAL INTERN

Amanda Cuomo

CME DEVELOPMENT MANAGERS

Annette Schwind
Shelley Wong

ASSISTANT—CME ADMINISTRATION

Sonny Santana

ART DIRECTOR

Derek Oscarson

GRAPHIC DESIGNER

Michael J. Vodilko

CHIEF FINANCIAL OFFICER

John Spano

ACCOUNTING INTERN

Stephanie Spano

SALES & EVENT COORDINATOR

Kimberly Schneider

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

CORPORATION COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross

MBL
communications

Publishers of

PRIMARY PSYCHIATRY
The Largest Peer-Reviewed Psychiatric Journal in the Nation

CNS SPECTRUMS
The International Journal of Neuropsychiatric Medicine

Psychiatry Weekly
The Leading News Service from Psychiatry and Psychiatry's Society

ADS
ALZHEIMER'S DISEASE SUMMIT
The World's Premier Alzheimer's Disease Summit

Master Psychopharmacology Program













The Master Psychopharmacology Program is intended as recognition for study in psychopharmacology that goes far beyond keeping CME up to date. Completion of the Master Psychopharmacology Program shows serious interest and investment in the field by those who attain Master Psychopharmacologist recognition. The program consists of 10 self-assessment exams (SAEs), each covering an individual topic, 24 online Fellowship activities, and one final exam. Candidates have 12 months to fulfill these requirements, and achieve the Master Psychopharmacologist designation.

NEI Membership

\$199 / year





Self-Assessment Exams (Online)

10 exams

- | | |
|--|--|
|  Basic Neuroscience |  Substance Use Disorders |
|  Psychosis and Schizophrenia |  Dementia and Cognitive Function |
|  Unipolar Depression |  Fibromyalgia, Functional Somatic Syndromes, and Chronic Pain |
|  Bipolar Disorders |  Disorders of Sleep/Wake and Their Comorbidities With Psychiatric Illness |
|  Anxiety Disorders | |
|  ADHD | |

Fellowship Activities (Online)

24 activities

- | | |
|--|---|
|  6 Articles |  6 Case-Based Drills |
|  6 Audiovisual Snippets |  6 Animated Mechanisms of Action |

A different Fellowship activity is released once a week.

Final Exam (Online)

\$249 / attempt



Enroll today at www.neiglobal.com/mpp

EDITOR'S LETTER**172 A Decade of Editing *CNS Spectrums*: Back to the Future**Eric Hollander, MD, *Institute of Clinical Neuroscience***COMMUNIQUE****175 Selective Benefit of Donepezil on Oral Naming in Alzheimer's Disease in Men Compared to Women****CLINICAL UPDATES IN NEUROPSYCHIATRY**

- 178** • *Cognitive Decline Begins in Late 20s*
• *Cholesterol-Reducing Drugs May Lessen Brain Function*

TRENDS IN PSYCHOPHARMACOLOGY**179 Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Overview and Finding the Focus**Stephen M. Stahl, MD, PhD, *University of California—San Diego*; and Richard L. Davis, *Arbor Scientia***ORIGINAL RESEARCH****183 An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder**Anita H. Clayton, MD, *University of Virginia*; Susan G. Kornstein, MD, *Virginia Commonwealth University*; Gregory Rosas, PhD, Christine Guico-Pabia, MD, and Karen A. Tourian, MD, *Wyeth Research***197 Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants**Robert M. Berman, MD, *Bristol-Myers Squibb*; Maurizio Fava, MD, *Massachusetts General Hospital*; Michael E. Thase, MD, *University of Pennsylvania*; Madhukar H. Trivedi, MD, *University of Texas Southwestern Medical School*; René Swanink, MS, *Bristol-Myers Squibb*; Robert D. McQuade, PhD, William H. Carson, MD, *Otsuka Pharmaceutical Development & Commercialization*; David Adson, MD, *University of Minnesota*; Leslie Taylor, MD, *University of Wisconsin Medical School*; James Hazel, BSN, and Ronald N. Marcus, MD, *Bristol-Myers Squibb***CASE REPORTS****208 Theta Burst Stimulation in the Treatment of Incapacitating Tinnitus Accompanied by Severe Depression**Surjo R. Soekadar, MD, Carola Arfeller, MSc, Albrecht Riik, MD, Stefan K. Plontke, MD, and Christian Plewnia, MD, *University of Tuebingen***214 Attenuation of Apparent New-Onset Ocular Tics with Successful Treatment of PTSD**CPT(P) Patrick C. Hayes, MD, *Bayne Jones Army Community Hospital*; MAJ Charles L. Weber, DO, *1st Cavalry Division, Iraq*; Michael B. Gallagher, PsyD, *Bayne Jones Army Community Hospital*; and LTC Gary J. Drouillard, MD, *Tripler Army Medical Center*

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc., 333 Hudson Street, 7th Floor, New York, NY 10013. Application to mail Periodicals postage rates is pending at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to *CNS Spectrums*, 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$195; in-training \$85. For subscriptions: Tel: 212-328-0800; Fax: 212-328-0600; Web: www.cns-spectrums.com. Single issues: \$15 – E-mail ks@mbllcommunications.com

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., *CNS Spectrums*, LLC, or the editorial advisory board.

This month's issue of *CNS Spectrums*, as well as a host of educational resources, enduring materials, and archived issues, is available at www.cns-spectrums.com.

Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of *CNS Spectrums*, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.



Copyright © 2009 by MBL Communications, Inc. All rights reserved. Printed in the United States.

ADS

"From Current Practices to Future Therapies"

ALZHEIMER'S DISEASE SUMMIT

ALZHEIMER'S DISEASE SUMMIT 2009:

From Current Practices to Future Therapies

- Date:** Saturday, October 17, 2009
- Location:** Washington, DC
- Program Chairs:** Pierre N. Tariot, MD and Norman L. Relkin, MD, PhD
- Guest Panelists:** Russell Katz, MD, of the FDA and Cristina Sampaio, MD, PhD of the EMEA
- Guest Speaker:** Meryl Comer, member of the Alzheimer's Study Group

For more information, please call
212-328-0800 ext. 266 or visit www.alzsummit.com

For registration updates, please e-mail
ks@mbcommunications.com

MBL

Publishers of

PRIMARY PSYCHIATRY

CNS SPECTRUMS

Psychiatry Weekly

ADS

ALZHEIMER'S DISEASE SUMMIT